Top Tier NExT Applications from Academia Applicant PI Center

First Page		Document Content
Date: 2014-05-27 20:51:25 Sanford-Burnham Medical Research Institute Angiogenesis inhibitor Monoclonal antibody therapy Cancer immunotherapy Cambridge Antibody Technology Breast cancer treatment Medicine Cancer organizations Protein kinase inhibitor		Top Tier NExT Applications from Academia Applicant PI Center Add to Reading List Source URL: next.cancer.gov Download Document from Source Website File Size: 30,79 KB Share Document on Facebook

	# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,,#, Stephen M. Shaw 1,, Kim Wi DocID: 1vdls - View Document
	Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx DocID: 1uTyz - View Document
	FALL/WINTERUCSF Oncology Connection Oncologist Lawrence Fong, MD, is leading UCSF’s newly launched Cancer Immunotherapy Program DocID: 1tGAn - View Document
	Cancer Immunotherapy & Personalized Vaccines Alex Rubinsteyn Mount Sinai, Hammer Lab DocID: 1tBVB - View Document